Tradestie Institutional Equity Comparison Engine
DCTH vs CVM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DCTH Overall Edge
DCTH Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Delcath Systems Inc (DCTH) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CVM counters with relative strength in Valuation. Fundamentally, DCTH trades at N/M Forward P/E with 5.2% operating margin (+70.7% YoY revenue) versus CVM at 23.0x Forward P/E and 0.0% operating margin (-62.7% YoY). In options structure, DCTH sits in BREAKOUT (43rd %ile IV; Dealer Gamma Walls on Pro) against CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
CVM
DCTH N/M vs CVM 23.0x Fwd P/E
Growth & Margin Winner
DCTH
Op Margin 5.2% vs 0.0% ยท YoY +70.7% vs -62.7%
Momentum & Technical Winner
DCTH
1Y +128.6% vs -77.5% ยท 52W Pos 80% vs 10%
Options & Structure Winner
DCTH
BREAKOUT (43rd %ile IV) vs BREAKDOWN (N/A IV)
DCTH
NASDAQ
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.68
-4.23% 1D
Market Cap
$743.8M
1M Return
+39.77%
1Y Return
+128.57%
Forward P/E
N/M
Unified AI Score
35.9 / 100
SELL
Tech 50.0
Fund 38.0
Flow 60.0
Mom 54.0
CVM
NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap
$20.9M
1M Return
-11.17%
1Y Return
-77.48%
Forward P/E
23.0x
Unified AI Score
56.6 / 100
HOLD
Tech 60.0
Fund 54.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
DCTH +128.57%
CVM -77.48%
Spread: +196.36 pp (DCTH Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DCTH Revenue | CVM Revenue | DCTH Op. Margin | CVM Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2013 | $0M | $0M | -4179.6% | -12450.1% | DCTH |
| FY2014 | $0M | $0M | -1805.8% | -9721.4% | DCTH |
| FY2015 | $0M | N/A | -870.6% | N/A | DCTH |
| FY2021 | $0M | N/A | -690.0% | N/A | DCTH |
| FY2022 | $0M | N/A | -1245.1% | N/A | DCTH |
| FY2023 | $0M | N/A | -1849.0% | N/A | DCTH |
| FY2024 | $40M | N/A | -33.4% | N/A | DCTH |
| FY2025 | $90M | N/A | 0.8% | N/A | DCTH |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DCTH | CVM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $743.8M | $20.9M | Larger Scale | DCTH |
| Trailing P/E Ratio Valuation | 133.6x | 23.0x | Lower Multiple | CVM |
| Forward P/E Ratio Valuation | N/M | 23.0x | Lower Multiple | CVM |
| Revenue Growth (YoY) Growth | +70.7% | -62.7% | Higher Growth | DCTH |
| Operating Margin (TTM) Profitability | 5.2% | 0.0% | Higher Margin | DCTH |
| Net Profit Margin Profitability | 6.0% | 0.0% | Higher Margin | DCTH |
| Return on Equity (ROE) Capital Efficiency | 5.4% | -252.5% | Higher ROE | DCTH |
| 52-Week Range Position Momentum | 80% ($8โ$23) | 10% ($1โ$8) | Stronger Trend | DCTH |
| Beta / 30D Volatility Risk Regime | 1.63ฮฒ ยท 131% Vol | 0.65ฮฒ ยท 120% Vol | Lower Realized Risk | CVM |
| Unified Institutional Score Composite Signal | 35.9 / 100 (SELL) | 56.6 / 100 (HOLD) | Higher Composite | CVM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full DCTH vs CVM Buy Guide
DCTH
BREAKOUT
66d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
43rd %ile
IV Regime
Balanced (25thโ60th %ile)
CVM
BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither DCTH nor CVM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.